Health and Healthcare

6 Biotech and Medtech Stocks That Saw Massive Moves Last Week

Chris Lange

Published: April 14, 2018 8:35 am

Last Updated: January 12, 2020 1:26 am

Over the past week, a few biotech companies made absolutely massive runs, while others fell off a cliff. Although health care has barely kept pace with the broader markets over the past 52 weeks, the way that some stocks have been trading in 2018 could make this an exciting year full of positive trials, U.S. Food and Drug Administration (FDA) approvals, as well as mergers and acquisitions.

24/7 Wall St. has picked a few of the standouts from the past week to highlight. We have included information about each company, as well as recent trading activity and the consensus analyst price target.

Menlo Therapeutics

Menlo Therapeutics Inc. (NASDAQ: MNLO) shares were slaughtered early on Monday after the firm issued an update for its midstage clinical trial for patients with atopic dermatitis. Unfortunately, the results did not live up to expectations, and it may be back to the drawing board for Menlo.

The firm announced top-line results from MTI-103 (ATOMIK), the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis. The study did not meet its primary or key secondary efficacy endpoints, with no statistically significant difference demonstrated between the serlopitant treated groups and the placebo-treated group.

Over the course of the week, shares fell 73%. The stock traded at $9.41 on Friday’s close. The consensus price target is $35.50, and the 52-week trading range is $7.94 to $39.86.

Therapix Biosciences

Therapix Biosciences Ltd. (NASDAQ: TRPX) shares saw a solid gain to start the week after it announced topline results for its cannabinoid product platform. Ultimately, the study found that subjects with Tourette syndrome benefited from the treatment, which is a big step forward for cannabinoid medicines.

The firm announced topline results from its investigator-initiated Phase 2a study at Yale University, which suggest that THX-110 significantly improved symptoms over time in adult subjects with Tourette syndrome.

The primary endpoint of the study was to assess the performance of THX-110 in the treatment of adult patients suffering from symptoms of Tourette syndrome, as measured by the Yale Global Tic Severity Scale Total Tic Score, the gold-standard and customary index for assessing symptom severity.

The study showed that these 16 subjects with medication-refractory Tourette syndrome had a reduction of tic symptoms from the baseline. This resulted in an average tic reduction of 21% across the entire sample.

In the past week, shares fell 4% and traded at $5.00 on Friday’s close. The consensus price target is $18.00, and the 52-week range is $4.26 to $7.83.

Spectrum Pharmaceuticals

Shares of Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) saw a handy gain early on Tuesday after the firm provided an update on its midstage non-small cell lung cancer (NSCLC) study. Specifically, the firm updated its poziotinib Phase 2 data in MD Anderson’s EGFR Exon 20 Mutant NSCLC.

Overall, these early data from MD Anderson suggest poziotinib may have a meaningful impact on outcomes for patients who have limited treatment options. The response for patients enrolling in the study has been strong, according to management.

The preliminary confirmed objective response rate and potential progression-free survival benefit in EGFR Exon 20 Mutant NSCLC patients have been significant. In the first 11 patients, the confirmed objective response rate was 64%. In the study, Spectrum was initially hoping to get response rates between 20% and 30%.

Last week, shares rose 34%, and they were last seen at $19.22 apiece. The 52-week range is $5.47 to $23.50, and the consensus price target is $29.25.

Selecta Biosciences

Selecta Biosciences Inc. (NASDAQ: SELB) saw its shares sink on Tuesday after the company presented new data from patients receiving SEL-212 for the treatment of chronic severe gout at the Pan American League of Associations for Rheumatology 2018 Congress in Argentina. Although the data seems positive, investors sent the stock lower.

According to the study, roughly 75% of evaluable patients maintained serum uric acid level control below 6 mg/dl during the initial three months of therapy with concurrent mitigation of ADAs against the pegsiticase enzyme. Even then, 91% of patients dosed with pegsiticase alone in month four after the initial three monthly doses of SEL-212 maintained serum uric acid control demonstrating the potential of SVP technology for the induction of immune tolerance.

Approximately 25% of the patient population treated with SEL-212 in the ongoing Phase 2 trial experienced gout flares during the first month after treatment with continued reduction of gout flare rates over months two to five. This low rate of gout flares appears to be in contrast with higher incidence of gout flares reported in clinical trials involving other urate-lowering therapies.

Shares rose 24.5% last week. The stock ended the week at $12.70, in a 52-week range of $7.95 to $24.02. The consensus analyst target is $25.20.

24/7 Wall St.
7 Companies That Have Raised Their Dividends for at Least 50 Straight Years

Analogic

Analogic Corp. (NASDAQ: ALOG) shares took a big step back on Wednesday after the firm announced that it would be acquired. Usually, when companies are being acquired they receive a premium on their share price. This does not seem to be the case for Analogic.

Under the terms of the deal, Analogic will be acquired by Altaris for $84 per share in cash, or roughly $1.1 billion in total. The transaction and the merger agreement were unanimously approved by Analogic’s board of directors, and the board unanimously recommends that Analogic’s stockholders vote in favor of the transaction.

The transaction represents a 25% premium to the closing share price of $67.45 on June 7, 2017, the day after Analogic reported quarterly earnings for the third quarter of fiscal 2017 and announced the launch of its strategic review process.

Shares fell 12% last week. The stock was at $83.50 a share on Friday’s close. The consensus price target is $89.50, and the 52-week range is $66.00 to $101.80.

Bellicum Pharmaceuticals

Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM) saw its shares rise early on Thursday after the firm announced a critical decision from the FDA. As we have said before, FDA decisions can make or break health care companies. In this case, Bellicum saw a handy gain.

The firm announced that the FDA lifted the clinical hold on studies of BPX-501 in the United States. The decision follows consultation with the FDA and agreement on amendments to the study protocols, including guidance on monitoring and management of neurologic adverse events.

Bellicum will be working with U.S. clinical sites to resume patient recruitment based on the amended protocols. The FDA clinical hold did not affect the BP-004 registrational trial in Europe, which is fully enrolled.

Last week, shares rose 40.5% and were last seen trading at $8.98 apiece. The 52-week trading range is $5.02 to $14.49 and the consensus price target is $20.00.